<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients - Penninga, L - 2013 | Cochrane Library</title> <meta content="Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients - Penninga, L - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008817.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients - Penninga, L - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008817.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008817.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients" name="citation_title"/> <meta content="Luit Penninga" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="LP@ctu.dk" name="citation_author_email"/> <meta content="Elisabeth I Penninga" name="citation_author"/> <meta content="Bispebjerg Hospital" name="citation_author_institution"/> <meta content="Christian H Møller" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Martin Iversen" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Daniel A Steinbrüchel" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD008817.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/05/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008817.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008817.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008817.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bronchiolitis Obliterans [prevention &amp; control]; Cyclosporine [adverse effects, *therapeutic use]; Diabetes Mellitus [chemically induced]; Graft Rejection [*prevention &amp; control]; Hypertension [prevention &amp; control]; Immune Tolerance; Immunosuppression Therapy [*methods]; Immunosuppressive Agents [adverse effects, *therapeutic use]; Lung Transplantation [*immunology]; Randomized Controlled Trials as Topic; Tacrolimus [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008817.pub2&amp;doi=10.1002/14651858.CD008817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="f00EizoA";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008817\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008817\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008817.pub2",title:"Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients",firstPublishedDate:"May 31, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008817.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008817.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008817.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008817.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008817.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008817.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008817.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008817.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008817.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008817.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3403 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008817.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-sec1-0006"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/appendices#CD008817-sec1-0012"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/table_n/CD008817StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/table_n/CD008817StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/information#CD008817-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Luit Penninga</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/information#CD008817-cr-0003">Elisabeth I Penninga</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/information#CD008817-cr-0004">Christian H Møller</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/information#CD008817-cr-0005">Martin Iversen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/information#CD008817-cr-0006">Daniel A Steinbrüchel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008817.pub2/information#CD008817-cr-0007">Christian Gluud</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/information/en#CD008817-sec1-0014">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 May 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008817.pub2">https://doi.org/10.1002/14651858.CD008817.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008817-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008817-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008817-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008817-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008817-abs-0001" lang="en"> <section id="CD008817-abs1-0001"> <h3 class="title" id="CD008817-abs1-0001">Background</h3> <p>Lung transplantation is a well‐accepted treatment for people with most end‐stage lung diseases. Although both tacrolimus and cyclosporin are used as primary immunosuppressive agents in lung transplant recipients, it is unclear which of these drugs is better in reducing rejection and death without causing adverse effects. </p> </section> <section id="CD008817-abs1-0002"> <h3 class="title" id="CD008817-abs1-0002">Objectives</h3> <p>To assess the benefits and harms of tacrolimus versus cyclosporin for primary immunosuppression in lung transplant recipients. </p> </section> <section id="CD008817-abs1-0003"> <h3 class="title" id="CD008817-abs1-0003">Search methods</h3> <p>We searched the Cochrane Renal Group's Specialised Register to 10 April 2013 through contact with the Trials Search Co‐ordinator using search terms relevant to this review. We also searched Science Citation Index Expanded and the Transplant Library to 20 April 2013. </p> </section> <section id="CD008817-abs1-0004"> <h3 class="title" id="CD008817-abs1-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCT) that compared any dose and duration of administration of tacrolimus versus cyclosporin as primary immunosuppressive treatment in lung transplant recipients. Our selection criteria required that all included patients received the same additional immunosuppressive therapy within each study. </p> </section> <section id="CD008817-abs1-0005"> <h3 class="title" id="CD008817-abs1-0005">Data collection and analysis</h3> <p>Three authors extracted data. For dichotomous data we used risk ratio (RR) and used mean difference (MD) for continuous data, each with 95% confidence intervals (CI). Methodological components of the included studies were used to assess risk of systematic errors (bias). Trial sequential analysis was used to assess risk of random errors (play of chance). </p> </section> <section id="CD008817-abs1-0006"> <h3 class="title" id="CD008817-abs1-0006">Main results</h3> <p>We included three studies that enrolled a total of 413 adult patients that compared tacrolimus with microemulsion or oral solution cyclosporin. All studies were found to be at high risk of bias. Tacrolimus seemed to be significantly superior to cyclosporin regarding the incidence of bronchiolitis obliterans syndrome (RR 0.46, 95% CI 0.29 to 0.74), lymphocytic bronchitis score (MD ‐0.60, 95% CI ‐1.04 to ‐0.16), treatment withdrawal (RR 0.27, 95% CI 0.16 to 0.46), and arterial hypertension (RR 0.67, 95% CI 0.50 to 0.89). However, the finding for arterial hypertension was not confirmed when analysed using a random‐effects model (RR 0.54, 95% CI 0.17 to 1.73). Furthermore, trial sequential analysis found that none of the meta‐analyses reached the required information sizes and cumulative Z‐curves did not cross trial sequential monitoring boundaries. Diabetes mellitus occurred more frequently among people in the tacrolimus group compared with the cyclosporin group when the fixed‐effect model was applied (RR 4.24, 95% CI 1.58 to 11.40), but no difference was found when the random‐effects model was used for analysis (RR 4.43, 95% CI 0.75 to 26.05). Again, trial sequential analysis found that the required information threshold was not reached and cumulative Z‐curve did not cross the trial sequential monitoring boundary. No significant difference between treatment groups was observed regarding mortality (RR 1.06, 95% CI 0.75 to 1.49), incidence of acute rejection (RR 0.89, 95% CI 0.77 to 1.03), numbers of infections/100 patient‐days (MD ‐0.15, 95% CI ‐0.30 to 0.00), cancer (RR 0.21, 95% CI 0.04 to 1.16), kidney dysfunction (RR 1.41, 95% CI 0.93 to 2.14), kidney failure (RR 1.57, 95% CI 0.28 to 8.94), neurotoxicity (RR 7.06, 95% CI 0.37 to 135.19), and hyperlipidaemia (RR 0.60, 95% CI 0.30 to 1.20). Trial sequential analysis showed the required information thresholds were not reached for any of these outcome measures. </p> </section> <section id="CD008817-abs1-0007"> <h3 class="title" id="CD008817-abs1-0007">Authors' conclusions</h3> <p>Tacrolimus may be superior to cyclosporin regarding bronchiolitis obliterans syndrome, lymphocytic bronchitis, treatment withdrawal, and arterial hypertension, but may be inferior regarding development of diabetes. No difference in mortality and acute rejection was observed between patients treated with tacrolimus and cyclosporin. There were few studies comparing tacrolimus and cyclosporin after lung transplantation, and the numbers of patients and events in the included studies were limited. Furthermore, the included studies were deemed to be at high risk of bias. Hence, more RCTs are needed to assess the results of the present review. Such studies ought to be conducted with low risks of systematic errors (bias) and of random errors (play of chance). </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008817-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008817-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008817-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008817-abs-0005">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008817-abs-0004" lang="en"> <h3>Which drug to prevent lung transplant rejection provides best results with fewest adverse effects? </h3> <p>Almost everyone who receives a lung transplant is treated with the drugs tacrolimus or cyclosporin to prevent transplanted organ rejection. Both drugs have serious and common adverse effects. We aimed to compare the use of tacrolimus with cyclosporin to prevent organ rejection after lung transplantation to assess which drug worked best and had fewest adverse effects. </p> <p>We identified three randomised controlled trials that compared tacrolimus with cyclosporin in patients who had received lung transplants. We found no difference in survival or rejection of the donated lungs with the drugs in lung transplant recipients. Tacrolimus seemed better in preventing serious inflammatory lung and airways diseases (bronchiolitis obliterans syndrome and lymphocytic bronchitis), and high blood pressure. Diabetes may occur more often in patients treated with tacrolimus compared with cyclosporin‐treated patients. More patients who received tacrolimus continued treatment compared with those treated with cyclosporin. </p> <p>However, these observations should be viewed cautiously because all three trials were flawed in design, the ways they were conducted, and in random errors. There were very few trials found that compared tacrolimus and cyclosporin after lung transplantation, and the numbers of patients and events were low. </p> <p>Better‐designed and conducted studies are needed to inform clinical decisions for people who receive lung transplants. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008817-sec1-0007" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008817-sec1-0007"></div> <h3 class="title" id="CD008817-sec1-0008">Implications for practice</h3> <section id="CD008817-sec1-0008"> <p>This review was limited by the small number of included studies, few numbers of participants, and high risks of bias in the included studies. Our analysis results suggested that tacrolimus may be superior to cyclosporin in lung transplant recipients regarding the incidence of bronchiolitis obliterans syndrome, lymphocytic bronchitis, treatment withdrawals and arterial hypertension, but may be inferior with regard to new‐onset diabetes mellitus. </p> <p>No significant difference was seen between the treatment groups in mortality, incidence of acute rejection, infection, cancer, treatment withdrawals, kidney failure, renal dysfunction, serum creatinine, and hyperlipidaemia. </p> <p>When trial sequential analysis was applied, none of the analyses achieved required information size. Hence, random errors could not be excluded. </p> </section> <h3 class="title" id="CD008817-sec1-0009">Implications for research</h3> <section id="CD008817-sec1-0009"> <p>Given the result of our analysis, the limited numbers of randomised studies and participants, it appeared that an appropriately powered RCT of tacrolimus versus cyclosporin using contemporary target levels and adjunctive immunosuppression in pulmonary transplantation is warranted to determine if the results of our meta‐analysis can be confirmed and extended. Such studies ought to be conducted with low risks of systematic error (bias) and of random error (play of chance). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008817-sec1-0001" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008817-sec1-0001"></div> <div class="table" id="CD008817-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tacrolimus compared to cyclosporin for lung transplant recipients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus compared to cyclosporin for lung transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Lung transplant recipients <br/> <b>Intervention:</b> Tacrolimus <br/> <b>Comparison:</b> Cyclosporin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Cyclosporin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tacrolimus</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b> <br/> Mortality at latest follow‐up <br/> Follow‐up: 2.2 to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.06</b> <br/> (0.75 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>413 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>226 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> <br/> (169 to 337) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>196 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>208 per 1000</b> <br/> (147 to 292) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acute rejection</b> <br/> The number of patients who experienced at least one episode of rejection <br/> Follow‐up: mean 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.89</b> <br/> (0.77 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>323 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>728 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>648 per 1000</b> <br/> (561 to 765) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>700 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b> <br/> (539 to 735) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Bronchiolitis obliterans syndrome</b> <br/> The number of patients diagnosed with the bronchiolitis obliterans syndrome <br/> Follow‐up: 2.2 to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.46</b> <br/> (0.29 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>413 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>231 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>106 per 1000</b> <br/> (67 to 171) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>208 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> <br/> (60 to 154) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Infection</b> <br/> The number of overall infections per 100 patient days <br/> Follow‐up: mean 1.4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean infection in the intervention groups was <br/> <b>0.15 lower</b> <br/> (0.3 lower to 0 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal</b> <br/> the number of patients stopping the assigned drug intervention <br/> Follow‐up: 2.2 to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> <br/> (42 to 119) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.27</b> <br/> (0.16 to 0.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>413 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Arterial hypertension</b> <br/> Follow‐up: 2.2 to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.67</b> <br/> (0.5 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>164 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>614 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>412 per 1000</b> <br/> (307 to 547) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>599 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>401 per 1000</b> <br/> (300 to 533) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Diabetes mellitus</b> <br/> Follow‐up: 2.2 to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.24</b> <br/> (1.58 to 11.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>164 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> <br/> (76 to 549) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>187 per 1000</b> <br/> (70 to 502) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹All included studies were at high risk of bias as assessed using the Cochrane risk of bias tool <br/> ²Large and consistent intervention effect in the included studies <br/> ³The only included study was assessed as high risk of bias using the Cochrane risk of bias tool </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008817-sec1-0002" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008817-sec1-0002"></div> <section id="CD008817-sec2-0001"> <h3 class="title" id="CD008817-sec2-0001">Description of the condition</h3> <p>Since the early 1980s, lung transplantation has enjoyed increasing success to become a well‐accepted treatment for many people with end‐stage lung diseases. Worldwide, more than 30,000 lung transplantations have been reported to the International Society for Heart and Lung Transplantation (<a href="./references#CD008817-bbs2-0013" title="ChristieJD , EdwardsLB , AuroraP , DobbelsF , KirkR , RahmelAO , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐sixth Official Adult Lung and Heart‐Lung Transplantation Report‐2009. Journal of Heart &amp; Lung Transplantation2009;28(10):1031‐49. [MEDLINE: 19782285] ">Christie 2009</a>). Currently, more than 2700 lung transplantations are reported annually worldwide, with one year survival of over 80%, and five year survival of 60% (<a href="./references#CD008817-bbs2-0010" title="AuroraP , EdwardsLB , ChristieJD , DobbelsF , KirkR , RahmelAO , et al. Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Lung and Heart/Lung Transplantation Report‐2009. Journal of Heart &amp; Lung Transplantation2009;28(10):1023‐30. [MEDLINE: 19782284] ">Aurora 2009</a>; <a href="./references#CD008817-bbs2-0013" title="ChristieJD , EdwardsLB , AuroraP , DobbelsF , KirkR , RahmelAO , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐sixth Official Adult Lung and Heart‐Lung Transplantation Report‐2009. Journal of Heart &amp; Lung Transplantation2009;28(10):1031‐49. [MEDLINE: 19782285] ">Christie 2009</a>). </p> <p>However, achieving long‐term survival after lung transplantation remains challenging, due mainly to the occurrence of bronchiolitis obliterans syndrome. Bronchiolitis obliterans syndrome and late graft failure are responsible for more than 40% of deaths beyond the first year of transplantation (<a href="./references#CD008817-bbs2-0013" title="ChristieJD , EdwardsLB , AuroraP , DobbelsF , KirkR , RahmelAO , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐sixth Official Adult Lung and Heart‐Lung Transplantation Report‐2009. Journal of Heart &amp; Lung Transplantation2009;28(10):1031‐49. [MEDLINE: 19782285] ">Christie 2009</a>). Bronchiolitis obliterans syndrome, also called obliterative bronchiolitis or constrictive bronchiolitis, is a non‐reversible obstructive lung disease in which the bronchioles are affected and narrowed by inflammation and fibrosis. It has become clear that acute rejection and lymphocytic bronchitis are primary risk factors for the development of the bronchiolitis obliterans syndrome in lung transplant recipients (<a href="./references#CD008817-bbs2-0025" title="HollmenM , TikkanenJM , NykanenAI , KoskinenPK , LemstromKB . Tacrolimus treatment effectively inhibits progression of obliterative airway disease even at later stages of disease development. Journal of Heart &amp; Lung Transplantation2008;27(8):856‐64. [MEDLINE: 18656798] ">Hollmen 2008</a>). Lung transplant recipients are also at high risk of developing co‐morbidities that contribute to limiting long‐term survival. These include hypertension (85%, five years after transplantation), kidney dysfunction (36%, five years after transplantation), hyperlipidaemia (55%, 5 years after transplantation), and diabetes mellitus (37%, five years after transplantation)(<a href="./references#CD008817-bbs2-0013" title="ChristieJD , EdwardsLB , AuroraP , DobbelsF , KirkR , RahmelAO , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐sixth Official Adult Lung and Heart‐Lung Transplantation Report‐2009. Journal of Heart &amp; Lung Transplantation2009;28(10):1031‐49. [MEDLINE: 19782285] ">Christie 2009</a>). </p> </section> <section id="CD008817-sec2-0002"> <h3 class="title" id="CD008817-sec2-0002">Description of the intervention</h3> <p>To prevent rejection and reduce cardiovascular risk factors, thereby increasing long‐term survival, it is essential to find the best immunosuppressive treatment strategy. Maintenance immunosuppressive therapy in lung transplantation often involves three types of drugs directed against the T‐cell activation and proliferation cascade: antiproliferative agents (mycophenolate mofetil or azathioprine), steroids (prednisolone), and calcineurin inhibitors (<a href="./references#CD008817-bbs2-0026" title="HopkinsPM , McNeilK . Evidence for immunosuppression in lung transplantation. Current Opinion in Organ Transplantation2008;13(5):477‐83. [MEDLINE: 19060529] ">Hopkins 2008</a>). Two calcineurin inhibitors, cyclosporin and tacrolimus, are currently used as immunosuppression therapy in lung transplant recipients, and have been essential in reducing the frequency of acute rejection and improving early survival (<a href="./references#CD008817-bbs2-0029" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). European respiratory monographs: lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009a</a>). </p> <p>Cyclosporin is a lipophilic cyclic undecapeptide with one unique amino acid in its structure. It was originally derived from the filamentous fungus <i>Tolypocladium inflatum (</i><a href="./references#CD008817-bbs2-0033" title="KapturczakMH , Meier‐KriescheHU , KaplanB . Pharmacology of calcineurin antagonists. Transplantation Proceedings2004;36(2 Suppl):25S‐32S. [MEDLINE: 15041303] ">Kapturczak 2004</a>)<i>.</i> Cyclosporin was discovered in 1971, and in 1983 the US Food and Drug Administration approved the drug for the prevention and treatment of transplant rejection (<a href="./references#CD008817-bbs2-0033" title="KapturczakMH , Meier‐KriescheHU , KaplanB . Pharmacology of calcineurin antagonists. Transplantation Proceedings2004;36(2 Suppl):25S‐32S. [MEDLINE: 15041303] ">Kapturczak 2004</a>). To address the intra‐ and inter‐individual differences in absorption and oral bioavailability of the original oil‐based formulation of cyclosporin (Sandimmune), a new microemulsion formula of cyclosporin (Neoral) was introduced in the 1990s (<a href="./references#CD008817-bbs2-0012" title="CantarovichM , BarkunJ , GiannettiN , CecereR , BesnerJG , TchervenkovJ . History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion. Transplantation Proceedings2004;36(2 Suppl):442S‐7S. [MEDLINE: 15041383] ">Cantarovich 2004</a>; <a href="./references#CD008817-bbs2-0016" title="DunnCJ , WagstaffAJ , PerryCM , PloskerGL , GoaKL . Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion‐based formulation (Neoral ®) in organ transplantation. Drugs2001;61(13):1957‐2016. [MEDLINE: 11708766] ">Dunn 2001</a>; <a href="./references#CD008817-bbs2-0032" title="KahanBD . Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplantation Proceedings2004;36(2 Suppl):378S‐91S. [MEDLINE: 15041372] ">Kahan 2004</a>; <a href="./references#CD008817-bbs2-0036" title="LeeKL , LeeKT , ChungHM , LinYP . Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM in renal transplant recipients. Transplantation Proceedings1998;30(7):3526‐9. [MEDLINE: 9838545] ">Lee 1998</a>). A modified cyclosporin formulation (Gengraf), which has a better absorption profile than the original oil‐based formulation, is currently available (<a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a>). </p> <p>Tacrolimus (Prograf) is a macrolide derived from the fungus <i>Streptomyces tsukubaensis</i>, and was developed as an alternative to cyclosporin. Tacrolimus was discovered in the early 1980s, and since 1989 has been used to prevent and treat liver transplantation rejection (<a href="./references#CD008817-bbs2-0033" title="KapturczakMH , Meier‐KriescheHU , KaplanB . Pharmacology of calcineurin antagonists. Transplantation Proceedings2004;36(2 Suppl):25S‐32S. [MEDLINE: 15041303] ">Kapturczak 2004</a>; <a href="./references#CD008817-bbs2-0048" title="StarzlTE , TodoS , FungJ , DemetrisAJ , VenkatarammanR , JainA . FK 506 for liver, kidney, and pancreas transplantation. Lancet1989;2(8670):1000‐4. [MEDLINE: 2478846] ">Starzl 1989</a>). Use of tacrolimus subsequently expanded rapidly into transplantation management of other organs (<a href="./references#CD008817-bbs2-0033" title="KapturczakMH , Meier‐KriescheHU , KaplanB . Pharmacology of calcineurin antagonists. Transplantation Proceedings2004;36(2 Suppl):25S‐32S. [MEDLINE: 15041303] ">Kapturczak 2004</a>). </p> <p>Both cyclosporin and tacrolimus inhibit phosphatase calcineurin action. Calcineurin regulates the transport of nuclear factor of activated T‐cells, which is a transcription factor that regulates lymphokine gene transcription. Cyclosporin and tacrolimus exert their cellular effects on the action of calcineurin through different cytoplasmic receptors, as cyclosporin binds to cyclophilins and tacrolimus binds to FK‐binding proteins. Differences between cyclosporin and tacrolimus with regard to adverse effects, safety, and tolerability have been observed (<a href="./references#CD008817-bbs2-0031" title="JiangH , KobayashiM . Differences between cyclosporin A and tacrolimus in organ transplantation. Transplantation Proceedings1999;31(5):1978‐80. [MEDLINE: 10455942] ">Jiang 1999</a>), but the toxicodynamic molecular mechanism of both drugs is still largely unknown and the involvement of calcineurin inhibition in calcineurin inhibitor toxicity is unclear. </p> <p>Both cyclosporin and tacrolimus are known to be nephrotoxic (<a href="./references#CD008817-bbs2-0011" title="BechsteinWO . Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant International2000;13(5):313‐26. [MEDLINE: 11052266] ">Bechstein 2000</a>; <a href="./references#CD008817-bbs2-0015" title="DemirjianS , StephanyB , Abu RomehIS , BoumitriM , YamaniMH , PoggioED . Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients. Clinical Transplantation2009;23(3):351‐60. [MEDLINE: 19208105] ">Demirjian 2009</a>). Tacrolimus has been associated with more new‐onset diabetes mellitus and neurotoxic reactions, but with less hypertension and hypercholesterolaemia compared with cyclosporin (<a href="./references#CD008817-bbs2-0019" title="FlechnerSM , KobashigawaJ , KlintmalmG . Calcineurin inhibitor‐sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clinical Transplantation2008;22(1):1‐15. [MEDLINE: 18217899] ">Flechner 2008</a>; <a href="./references#CD008817-bbs2-0021" title="HeiselO , HeiselR , BalshawR , KeownP . New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta‐analysis. American Journal of Transplantation2004;4(4):583‐95. [MEDLINE: 15023151] ">Heisel 2004</a>; <a href="./references#CD008817-bbs2-0038" title="McAlisterVC , HaddadE , RenoufE , MalthanerRA , KjaerMS , GluudLL . Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta‐analysis. American Journal of Transplantation2006;6(7):1578‐85. [MEDLINE: 16827858] ">McAlister 2006</a>; <a href="./references#CD008817-bbs2-0041" title="MooreR , HernandezD , ValantineH . Calcineurin inhibitors and post‐transplant hyperlipidaemias. Drug Safety2001;24(10):755‐66. [MEDLINE: 11676303] ">Moore 2001</a>; <a href="./references#CD008817-bbs2-0042" title="PenningaL , MøllerCH , GustafssonF , SteinbrüchelDA , GluudC . Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta‐analyses and trial sequential analyses of randomised trials. European Journal of Clinical Pharmacology2010;66(12):1177‐87. [DOI: 10.1007/s00228‐010‐0902‐6] ">Penninga 2010a</a>; <a href="./references#CD008817-bbs2-0043" title="PhamSM , KormosRL , KawaiA , MuraliS , HattlerBG , DemetrisAJ , et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five‐year experience. Transplantation Proceedings1996;28(2):1002‐4. [MEDLINE: 8623208] ">Pham 1996</a>; <a href="./references#CD008817-bbs2-0053" title="VincentiF , FrimanS , ScheuermannE , RostaingL , JenssenT , CampistolJM , et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. American Journal of Transplantation2007;7(6):1506‐14. [MEDLINE: 17359512] ">Vincenti 2007</a>; <a href="./references#CD008817-bbs2-0058" title="WhiteM , HaddadH , LeBlancMH , GiannettiN , PflugfelderP , DaviesR , et al. Conversion from cyclosporine microemulsion to tacrolimus‐based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: The Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. Journal of Heart &amp; Lung Transplantation2005;24(7):798‐809. [MEDLINE: 15982605] ">White 2005</a>). Differences between tacrolimus and cyclosporin in preventing rejection have also been reported (<a href="./references#CD008817-bbs2-0038" title="McAlisterVC , HaddadE , RenoufE , MalthanerRA , KjaerMS , GluudLL . Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta‐analysis. American Journal of Transplantation2006;6(7):1578‐85. [MEDLINE: 16827858] ">McAlister 2006</a>; <a href="./references#CD008817-bbs2-0042" title="PenningaL , MøllerCH , GustafssonF , SteinbrüchelDA , GluudC . Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta‐analyses and trial sequential analyses of randomised trials. European Journal of Clinical Pharmacology2010;66(12):1177‐87. [DOI: 10.1007/s00228‐010‐0902‐6] ">Penninga 2010a</a>; <a href="./references#CD008817-bbs2-0054" title="WebsterAC , TaylorRR , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003961.pub2] ">Webster 2005a</a>; <a href="./references#CD008817-bbs2-0055" title="WebsterAC , WoodroffeRC , TaylorRS , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta‐analysis and meta‐regression of randomised trial data. BMJ2005;331(7520):810. [MEDLINE: 16157605] ">Webster 2005b</a>). </p> </section> <section id="CD008817-sec2-0003"> <h3 class="title" id="CD008817-sec2-0003">How the intervention might work</h3> <p>Randomised controlled trials (RCT) and meta‐analyses of such studies comparing tacrolimus versus cyclosporin in other solid organ recipients have shown differences in graft survival and incidence of acute rejection in kidney, liver, and heart transplant recipients (<a href="./references#CD008817-bbs2-0038" title="McAlisterVC , HaddadE , RenoufE , MalthanerRA , KjaerMS , GluudLL . Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta‐analysis. American Journal of Transplantation2006;6(7):1578‐85. [MEDLINE: 16827858] ">McAlister 2006</a>; <a href="./references#CD008817-bbs2-0042" title="PenningaL , MøllerCH , GustafssonF , SteinbrüchelDA , GluudC . Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta‐analyses and trial sequential analyses of randomised trials. European Journal of Clinical Pharmacology2010;66(12):1177‐87. [DOI: 10.1007/s00228‐010‐0902‐6] ">Penninga 2010a</a>; <a href="./references#CD008817-bbs2-0054" title="WebsterAC , TaylorRR , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003961.pub2] ">Webster 2005a</a>; <a href="./references#CD008817-bbs2-0055" title="WebsterAC , WoodroffeRC , TaylorRS , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta‐analysis and meta‐regression of randomised trial data. BMJ2005;331(7520):810. [MEDLINE: 16157605] ">Webster 2005b</a>). Differences in morbidities such as diabetes, hyperlipidaemia, and hypertension have also been observed between these treatment groups (<a href="./references#CD008817-bbs2-0038" title="McAlisterVC , HaddadE , RenoufE , MalthanerRA , KjaerMS , GluudLL . Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta‐analysis. American Journal of Transplantation2006;6(7):1578‐85. [MEDLINE: 16827858] ">McAlister 2006</a>; <a href="./references#CD008817-bbs2-0042" title="PenningaL , MøllerCH , GustafssonF , SteinbrüchelDA , GluudC . Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta‐analyses and trial sequential analyses of randomised trials. European Journal of Clinical Pharmacology2010;66(12):1177‐87. [DOI: 10.1007/s00228‐010‐0902‐6] ">Penninga 2010a</a>; <a href="./references#CD008817-bbs2-0054" title="WebsterAC , TaylorRR , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003961.pub2] ">Webster 2005a</a>; <a href="./references#CD008817-bbs2-0055" title="WebsterAC , WoodroffeRC , TaylorRS , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta‐analysis and meta‐regression of randomised trial data. BMJ2005;331(7520):810. [MEDLINE: 16157605] ">Webster 2005b</a>). </p> </section> <section id="CD008817-sec2-0004"> <h3 class="title" id="CD008817-sec2-0004">Why it is important to do this review</h3> <p>The International Society for Heart and Lung Transplantation has reported that at both one and five years after lung transplantation tacrolimus is currently the most frequently used calcineurin inhibitor (<a href="./references#CD008817-bbs2-0013" title="ChristieJD , EdwardsLB , AuroraP , DobbelsF , KirkR , RahmelAO , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐sixth Official Adult Lung and Heart‐Lung Transplantation Report‐2009. Journal of Heart &amp; Lung Transplantation2009;28(10):1031‐49. [MEDLINE: 19782285] ">Christie 2009</a>). However, there is no consensus to date on the choice of tacrolimus versus cyclosporin for primary immunosuppressive therapy in lung transplant recipients (<a href="./references#CD008817-bbs2-0029" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). European respiratory monographs: lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009a</a>). RCTs comparing tacrolimus versus cyclosporin in lung transplant recipients have shown conflicting results and optimal immunosuppressive maintenance therapy in this population continues to be discussed (<a href="./references#CD008817-bbs2-0044" title="ReichenspurnerH . Overview of tacrolimus‐based immunosuppression after heart or lung transplantation. Journal of Heart &amp; Lung Transplantation2005;24(2):119‐30. [MEDLINE: 15701425] ">Reichenspurner 2005</a>). Clear evidence is essential to find the optimal and most effective immunosuppressive treatment strategy in lung transplant recipients, and to improve long‐term survival. It is of utmost importance for lung transplant recipients to identify which of the two drugs works best regarding survival and rejection, is best tolerated, and is associated with fewest adverse effects. A published meta‐analysis has reported fewer rejection episodes, but more new‐onset diabetes mellitus associated with tacrolimus compared with cyclosporin (<a href="./references#CD008817-bbs2-0018" title="FanY , XiaoYB , WengYG . Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta‐analysis. Transplantation Proceedings2009;41(5):1821‐4. [MEDLINE: 19545736] ">Fan 2009</a>). Fewer treatment withdrawals were also observed in patients treated with tacrolimus compared with cyclosporin (<a href="./references#CD008817-bbs2-0018" title="FanY , XiaoYB , WengYG . Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta‐analysis. Transplantation Proceedings2009;41(5):1821‐4. [MEDLINE: 19545736] ">Fan 2009</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008817-sec1-0003" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008817-sec1-0003"></div> <p>This review aimed to assess the benefits and harms of tacrolimus versus cyclosporin for primary immunosuppressive treatment in lung transplantation recipients. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008817-sec1-0004" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008817-sec1-0004"></div> <section id="CD008817-sec2-0005"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008817-sec3-0001"> <h4 class="title">Types of studies</h4> <p>All RCTs assessing tacrolimus versus cyclosporin for lung transplant patients, irrespective of blinding, publication status, or language were considered. Quasi‐RCTs and cohort studies identified from the searches were considered only for reporting of harms. </p> </section> <section id="CD008817-sec3-0002"> <h4 class="title">Types of participants</h4> <p>Adult and paediatric patients after first‐time single or double lung transplantation were included. </p> </section> <section id="CD008817-sec3-0003"> <h4 class="title">Types of interventions</h4> <p>Studies comparing any dose and duration of administration of tacrolimus versus cyclosporin as primary immunosuppression in lung transplant recipients. We required that all included patients received the same additional immunosuppressive therapy within each study. </p> </section> <section id="CD008817-sec3-0004"> <h4 class="title">Types of outcome measures</h4> <section id="CD008817-sec4-0001"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008817-lst1-0001"> <li> <p>Mortality</p> </li> <li> <p>Acute rejection</p> </li> <li> <p>Bronchiolitis obliterans syndrome</p> </li> <li> <p>Infection or sepsis.</p> </li> </ol> </p> </section> <section id="CD008817-sec4-0002"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008817-lst1-0002"> <li> <p>Quality of life</p> </li> <li> <p>Any adverse event. Serious adverse events were defined as any untoward medical occurrence that was life threatening, resulted in death, or persistent or significant disability, or any medical event, which might have jeopardised the patient, or required intervention to prevent it (<a href="./references#CD008817-bbs2-0028" title="European Medicines Agency. Guideline for good clinical practice. E6 (R1). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf(accessed February 2013). ">ICH‐GCP 2002</a>). All other adverse events (any medical occurrence not necessarily having a causal relationship with the treatment, but did however cause a dose reduction or discontinuation of the treatment) were considered as non‐serious. </p> </li> <li> <p>Withdrawals</p> </li> <li> <p>Lymphocytic bronchitis</p> </li> <li> <p>Pneumonia (viral, bacterial, and fungal)</p> </li> <li> <p>Cytomegalovirus infection</p> </li> <li> <p>Cancer</p> </li> <li> <p>Neurotoxic reaction</p> </li> <li> <p>Kidney failure</p> </li> <li> <p>Arterial hypertension</p> </li> <li> <p>Diabetes mellitus</p> </li> <li> <p>Hyperlipidaemia</p> </li> <li> <p>Hirsutism</p> </li> <li> <p>Gingival hyperplasia</p> </li> <li> <p>Serum creatinine</p> </li> <li> <p>Total cholesterol.</p> </li> </ol> </p> <p>All outcomes were assessed at latest follow‐up.</p> </section> </section> </section> <section id="CD008817-sec2-0006"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008817-sec3-0005"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Renal Group's Specialised Register to 10 April 2013 through contact with the Trials Search Co‐ordinator using search terms relevant to this review. </p> <p>The Cochrane Renal Group’s Specialised Register contains studies identified from:</p> <p> <ol id="CD008817-lst1-0003"> <li> <p>Quarterly searches of the Cochrane Central Register of Controlled Trials CENTRAL</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of renal‐related journals and the proceedings of major renal conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected renal journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies as well as a list of handsearched journals, conference proceedings and current awareness alerts are available in the Specialised Register section of information about the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Renal Group</a>. </p> <p>We also searched the following online resources:</p> <p> <ol id="CD008817-lst1-0004"> <li> <p>Science Citation Index Expanded (1945 to 20 April 2013)(<a href="./references#CD008817-bbs2-0045" title="RoyleP , WaughN . Literature searching for clinical and cost‐effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system. Health Technology Assessment2003;7(34):iii, ix‐51. [MEDLINE: 14609481] ">Royle 2003</a>). </p> </li> <li> <p>Transplant Library (1970 to 20 April 2013).</p> </li> </ol> </p> <p><a href="./appendices#CD008817-sec2-0016">Appendix 1</a> presents search terms used in strategies for this review. </p> </section> <section id="CD008817-sec3-0006"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD008817-lst1-0005"> <li> <p>Reference lists of respiratory and transplantation textbooks, review articles, and relevant studies. </p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies on the topic. </p> </li> </ol> </p> </section> </section> <section id="CD008817-sec2-0007"> <h3 class="title" id="CD008817-sec2-0007">Data collection and analysis</h3> <section id="CD008817-sec3-0007"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that might be relevant to the review. Two authors independently assessed study eligibility. Excluded studies were listed with the reason for exclusion. Disagreement was solved by discussion or in consultation with a third author. Study authors were contacted if information about methodology or data was unclear or missing (<a href="./references#CD008817-bbs2-0049" title="ThompsonSG , HigginsJP . How should meta‐regression analyses be undertaken and interpreted?. Statistics in Medicine2002;21(11):1559‐73. [MEDLINE: 12111920] ">Thompson 2002</a>). </p> </section> <section id="CD008817-sec3-0008"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by three authors using standard data extraction forms. Studies reported in non‐English language journals were planned to be translated before assessment. Where more than one publication of a study existed, reports were grouped together and only the publication with the most complete data were included (<a href="./references#CD008817-bbs2-0040" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006‐12. [MEDLINE: 19631508] ">Moher 2009</a>). Where relevant outcomes were only published in earlier versions these data were also used. Any discrepancy between published versions was highlighted. Any further information required from the original authors was requested by written correspondence and any relevant information obtained in this manner was included in the review. Disagreements were resolved by consultation with all authors. From each study we extracted the following information: first author, country of origin, study design, inclusion and exclusion criteria, number of participants, patients characteristics, single or double lung transplantation, study drugs: dose, trough levels, type of cyclosporin formulation (oil‐based capsules or micro‐emulsion capsules, or oral solution), administration, additional immunosuppressive therapy, follow‐up period, primary and secondary outcomes, adverse events, and patients lost for follow‐up. </p> </section> <section id="CD008817-sec3-0009"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were assessed using the risk of bias assessment tool (<a href="./references#CD008817-bbs2-0024" title="HigginsJP , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>)(see <a href="./appendices#CD008817-sec2-0017">Appendix 2</a>). </p> <p> <ul id="CD008817-lst1-0006"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)? </p> <ul id="CD008817-lst2-0001"> <li> <p>Participants and personnel</p> </li> <li> <p>Outcome assessors</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> <p>Studies with adequate generation of the allocation sequence, adequate allocation concealment, adequate blinding, adequate outcome data reporting, no selective outcome reporting, and without other interests were considered as studies with low risk of bias (high methodological quality)(<a href="./references#CD008817-bbs2-0024" title="HigginsJP , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>; <a href="./references#CD008817-bbs2-0035" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. [MEDLINE: 11730399] ">Kjaergard 2001</a>; <a href="./references#CD008817-bbs2-0039" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. [MEDLINE: 9746022] ">Moher 1998</a>; <a href="./references#CD008817-bbs2-0046" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [MEDLINE: 7823387] ">Schulz 1995</a>). Studies with one or more unclear or inadequate quality components were considered as studies with high risk of bias (low methodological quality)(<a href="./references#CD008817-bbs2-0024" title="HigginsJP , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>; <a href="./references#CD008817-bbs2-0035" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. [MEDLINE: 11730399] ">Kjaergard 2001</a>; <a href="./references#CD008817-bbs2-0039" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. [MEDLINE: 9746022] ">Moher 1998</a>; <a href="./references#CD008817-bbs2-0046" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [MEDLINE: 7823387] ">Schulz 1995</a>). High inter‐rater agreement between blinded and unblinded assessments as well as between two independent assessors has been found previously (<a href="./references#CD008817-bbs2-0020" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493‐501. [MEDLINE: 16443796] ">Gluud 2006</a>; <a href="./references#CD008817-bbs2-0035" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. [MEDLINE: 11730399] ">Kjaergard 2001</a>). As tacrolimus and cyclosporin are usually dosed on trough levels (or currently two hours post‐dose levels for cyclosporin) studies are expected to be open label and without adequate blinding, which might increase the risk of bias. </p> </section> <section id="CD008817-sec3-0010"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement are used to assess the effects of treatment the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales have been used. </p> </section> <section id="CD008817-sec3-0011"> <h4 class="title">Dealing with missing data</h4> <p>When data were missing we took the following steps.</p> <p> <ul id="CD008817-lst1-0007"> <li> <p>We contacted the original investigators to request missing data.</p> </li> <li> <p>We analysed the missing data assuming that data are missing at random.</p> </li> <li> <p>For incomplete data, we performed sensitivity analyses to assess how sensitive results are to reasonable changes in the assumptions that are made. </p> </li> </ul> </p> </section> <section id="CD008817-sec3-0012"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi² test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<a href="./references#CD008817-bbs2-0022" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. [MEDLINE: 12111919] ">Higgins 2002</a>; <a href="./references#CD008817-bbs2-0023" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>; <a href="./references#CD008817-bbs2-0024" title="HigginsJP , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD008817-sec3-0013"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to construct funnel plots to explore bias (<a href="./references#CD008817-bbs2-0017" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [MEDLINE: 9310563] ">Egger 1997</a>; <a href="./references#CD008817-bbs2-0037" title="MacaskillP , WalterSD , IrwigL . A comparison of methods to detect publication bias in meta‐analysis. Statistics in Medicine2001;20(4):641‐54. [MEDLINE: 11223905] ">Macaskill 2001</a>) if more than 10 studies were identified for inclusion. Asymmetry in funnel plot of study size was planned to be used to assess this bias. We planned to perform linear regression approach to determine the funnel plot asymmetry (<a href="./references#CD008817-bbs2-0017" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [MEDLINE: 9310563] ">Egger 1997</a>). However, because only three studies met the review's inclusion criteria, funnel plots were not created nor proposed analyses conducted. </p> </section> <section id="CD008817-sec3-0014"> <h4 class="title">Data synthesis</h4> <p>The analyses were performed using Review Manager 5 and trial sequential analysis (<a href="./references#CD008817-bbs2-0051" title="EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC , ThorlundK . User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. Available from www.ctu.dk/tsa2011:1‐115. ">TSA 2011</a>; <a href="./references#CD008817-bbs2-0052" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. Available from www.ctu.dk/tsa2011. ">TSA Manual 2011</a>; <a href="./references#CD008817-bbs2-0056" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). Data were analysed using both fixed‐effect and random‐effects models. Where discrepancies occurred between models, both results were reported; otherwise only results from the fixed‐effect model were reported. Data were analysed according to the intention‐to‐treat principle and presented as RR and risk difference (RD) with 95% confidence intervals. </p> </section> <section id="CD008817-sec3-0015"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses were planned to be performed for:</p> <p> <ul id="CD008817-lst1-0008"> <li> <p>Studies with low risk of bias compared with studies with high risk of bias.</p> </li> <li> <p>Tacrolimus versus oil‐based cyclosporin compared with tacrolimus versus microemulsion cyclosporin studies. This subgroup analysis was planned because differences in absorption and oral bioavailability of the two formulae have been described (<a href="./references#CD008817-bbs2-0012" title="CantarovichM , BarkunJ , GiannettiN , CecereR , BesnerJG , TchervenkovJ . History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion. Transplantation Proceedings2004;36(2 Suppl):442S‐7S. [MEDLINE: 15041383] ">Cantarovich 2004</a>; <a href="./references#CD008817-bbs2-0032" title="KahanBD . Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplantation Proceedings2004;36(2 Suppl):378S‐91S. [MEDLINE: 15041372] ">Kahan 2004</a>; <a href="./references#CD008817-bbs2-0036" title="LeeKL , LeeKT , ChungHM , LinYP . Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM in renal transplant recipients. Transplantation Proceedings1998;30(7):3526‐9. [MEDLINE: 9838545] ">Lee 1998</a>; <a href="./references#CD008817-bbs2-0042" title="PenningaL , MøllerCH , GustafssonF , SteinbrüchelDA , GluudC . Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta‐analyses and trial sequential analyses of randomised trials. European Journal of Clinical Pharmacology2010;66(12):1177‐87. [DOI: 10.1007/s00228‐010‐0902‐6] ">Penninga 2010a</a>). </p> </li> <li> <p>Adult compared with paediatric studies. This was planned because immunological differences in paediatric patients might be expected (<a href="./references#CD008817-bbs2-0010" title="AuroraP , EdwardsLB , ChristieJD , DobbelsF , KirkR , RahmelAO , et al. Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Lung and Heart/Lung Transplantation Report‐2009. Journal of Heart &amp; Lung Transplantation2009;28(10):1023‐30. [MEDLINE: 19782284] ">Aurora 2009</a>; <a href="./references#CD008817-bbs2-0013" title="ChristieJD , EdwardsLB , AuroraP , DobbelsF , KirkR , RahmelAO , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐sixth Official Adult Lung and Heart‐Lung Transplantation Report‐2009. Journal of Heart &amp; Lung Transplantation2009;28(10):1031‐49. [MEDLINE: 19782285] ">Christie 2009</a>). </p> </li> <li> <p>Single compared with double lung transplant patients. Sub group analysis was planned because we anticipated differences between these populations (<a href="./references#CD008817-bbs2-0013" title="ChristieJD , EdwardsLB , AuroraP , DobbelsF , KirkR , RahmelAO , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐sixth Official Adult Lung and Heart‐Lung Transplantation Report‐2009. Journal of Heart &amp; Lung Transplantation2009;28(10):1031‐49. [MEDLINE: 19782285] ">Christie 2009</a>). </p> </li> <li> <p>Tacrolimus versus two hours post‐dose monitoring of cyclosporin (C2‐monitoring) compared with tacrolimus versus cyclosporin dosing based on trough levels (C0‐monitoring). This was planned to investigate reports of better outcomes for two hours post‐dose monitoring of cyclosporin (<a href="./references#CD008817-bbs2-0029" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). European respiratory monographs: lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009a</a>). </p> </li> </ul> </p> <p>Tests for subgroup differences were performed to evaluate differences between estimates.</p> </section> <section id="CD008817-sec3-0016"> <h4 class="title">Sensitivity analysis</h4> <section id="CD008817-sec4-0003"> <h5 class="title">Zero‐event studies</h5> <p>RevMan 5 was not designed to analyse studies with no events in both intervention groups when meta‐analyses are performed as RR or odds ratio (OR). Exclusion of zero event studies seemed to us to be unjustified and unreasonable, and potentially created risk of inflating the magnitude of the pooled treatment effects (<a href="./references#CD008817-bbs2-0034" title="KeusF , WetterslevJ , GluudC , GooszenHG , vanLaarhovenCJ . Robustness assessments are needed to reduce bias in meta‐analyses that include zero‐event randomized trials. American Journal of Gastroenterology2009;104(3):546‐51. [MEDLINE: 19262513] ">Keus 2009</a>). Therefore, we also performed a random‐effects meta‐analysis with empirical continuity correction of 0.01 in zero event studies. </p> </section> <section id="CD008817-sec4-0004"> <h5 class="title">Trial sequential analysis</h5> <p>Because cumulative meta‐analyses can produce random errors resulting from sparse data and repetitive testing on accumulating data, we conducted trial sequential analysis (<a href="./references#CD008817-bbs2-0050" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis ‐ a simulation study. PLoS One2011;6(10):e25491. [MEDLINE: 22028777] ">Thorlund 2011</a>; <a href="./references#CD008817-bbs2-0052" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. Available from www.ctu.dk/tsa2011. ">TSA Manual 2011</a>; <a href="./references#CD008817-bbs2-0056" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). We calculated the required number of participants needed in a meta‐analysis to detect or reject a certain intervention effect (the 'information size') to minimise random errors (<a href="./references#CD008817-bbs2-0056" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD008817-bbs2-0057" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. [MEDLINE: 20042080] ">Wetterslev 2009</a>). Required information size calculation can account for heterogeneity present in meta‐analyses. In our meta‐analysis, information size was based on the observed proportion with the focus outcome in the cyclosporin group, and on the assumption of a plausible relative risk reduction of 20%, or on the relative risk reduction observed in the included studies determined to be at low risk of bias (<a href="./references#CD008817-bbs2-0056" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). The underlying assumption of trial sequential analysis was that significance testing may be performed each time a new study was added to the cumulative meta‐analysis. We added studies according to the year of publication, but if more than one study was published in a year, studies were added alphabetically according to the last name of the first author. Trial sequential monitoring boundaries were constructed on the basis of the required information size and risk for type I (5%) and type II (20%) errors (<a href="./references#CD008817-bbs2-0051" title="EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC , ThorlundK . User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. Available from www.ctu.dk/tsa2011:1‐115. ">TSA 2011</a>; <a href="./references#CD008817-bbs2-0056" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). The purpose of these boundaries was to determine the statistical inference that could be drawn about the cumulative meta‐analysis that had not reached the required information size; if a trial sequential monitoring boundary is crossed before the required information size is reached in a cumulative meta‐analysis, firm evidence may have been established and further studies may be superfluous. On the other hand, if boundaries are not surpassed, it is probably necessary to continue doing studies to detect or reject a certain intervention effect. We applied type I errors of 5%, type II errors of 20% as defaults and adjusted information size for heterogeneity unless otherwise stated (<a href="./references#CD008817-bbs2-0052" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. Available from www.ctu.dk/tsa2011. ">TSA Manual 2011</a>; <a href="./references#CD008817-bbs2-0056" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008817-sec1-0005" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008817-sec1-0005"></div> <section id="CD008817-sec2-0008"> <h3 class="title">Description of studies</h3> <section id="CD008817-sec3-0017"> <h4 class="title">Results of the search</h4> <p>Our search identified 86 references. After exclusion of duplicates and references that did not match inclusion criteria, we identified three RCTs reported in 11 publications (three peer‐reviewed journal articles and eight conference abstracts) for analysis (<a href="#CD008817-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD008817-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD008817-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD008817-sec3-0018"> <h4 class="title">Included studies</h4> <p>We included three studies with a total of 413 adult participants. Of these, 205 were randomised to tacrolimus and 208 to cyclosporin (<a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a>; <a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a>; <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a>). <a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a> was a single‐centre study; <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> was conducted at two centres; and <a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a> was a multicentre study. </p> <p>Reported mean age of the total study population ranged from 44 to 50 years (<a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a>; <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a>). Mean age of participants in the single‐ and dual‐centre studies was similar (<a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a>; <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a>). </p> <p>All included studies reported on the number of single versus double lung transplant recipients. Most recipients were reported to have undergone double lung transplantations (62%, 74% and 93% respectively in <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a>; <a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a>; and <a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a>). Transplantation type was similar between the tacrolimus and cyclosporin treatment groups within each study. </p> <p><a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a> and <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> (323 participants) compared tacrolimus with the new formula microemulsion cyclosporin, and <a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a> (90 participants) compared tacrolimus with microemulsion (Neoral) or modified cyclosporin formulation (Gengraf). </p> <p>All patients in the three included studies were treated with steroids as well as the antiproliferative agents azathioprine (<a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a>) and mycophenolate mofetil (<a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a>; <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a>). Induction therapy immunosuppressive agents administered were basiliximab (20 mg on day 0 and day 4) and rat anti‐thymocyte globulin during the first three postoperative days in <a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a> and <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> respectively. <a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a> did not administer induction therapy. </p> <p>Follow‐up ranged from 2.2 years (<a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a>) to 3 years (<a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a>; <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a>). </p> </section> <section id="CD008817-sec3-0019"> <h4 class="title">Excluded studies</h4> <p>Following appraisal of full‐text articles six studies were excluded (<a href="./references#CD008817-bbs2-0004" title="BhoradeSM , VillanuevaJ , JordanAM , CreechS , LeischnerJ , VigneswerenWT , et al. A comparison of three tacrolimus based immunosuppressive regimens in lung transplantation. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):B13. ">Bhorade 2002</a>; <a href="./references#CD008817-bbs2-0005" title="FungJJ , StarzlTE . FK 506 in solid organ transplantation. Transplantation Proceedings1994;26(5):3017‐20. [EMBASE: 1994333111] ">Fung 1994</a>; <a href="./references#CD008817-bbs2-0006" title="GriffithBP , BandoK , HardestyRL , ArmitageJM , KeenanRJ , PhamSM , et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation1994;57(6):848‐51. [MEDLINE: 7512292] KeenanRJ , DauberJH , IaconoA . Long term follow up clinical trial of tacrolimus versus cyclosporin for lung transplantation. Journal of Heart &amp; Lung Transplantation1998;17(1):58. KeenanRJ , KonishiH , KawaiA , ParadisIL , NunleyDR , IaconoAT , et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Annals of Thoracic Surgery1995;60(3):580‐4. [MEDLINE: 7545889] McCurryKR , ZaldonisDB , KeenanRJ , DauberJH , BauldoffGS , HattlerBG , et al. Long term follow‐up of a prospective, randomized trial of tacrolimus versus cyclosporine in human lung transplantation [abstract]. American Journal of Transplantation2002;2(Suppl 3):159. ">Keenan 1995</a>; <a href="./references#CD008817-bbs2-0007" title="KestenS , ChaparroC , ScavuzzoM , GutierrezC . Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome. Journal of Heart &amp; Lung Transplantation1997;16(9):905‐12. [EMBASE: 1997294179] ">Kesten 1997</a>; <a href="./references#CD008817-bbs2-0008" title="KurF , ReichenspurnerH , MeiserBM , WelzA , FurstH , MullerC , et al. Tacrolimus (FK506) as primary immunosuppressant after lung transplantation. Thoracic &amp; Cardiovascular Surgeon1999;47(3):174‐8. [MEDLINE: 10443520] ">Kur 1999</a>; <a href="./references#CD008817-bbs2-0009" title="SchwaiblmairM , ReichenspurnerH , FurstH , BriegelJ , ReichartB , VogelmeierC . Comparative study between cyclosporin and tacrolimus in immune suppression after lung transplantation. Pneumologie2000;54:S90. ">Schwaiblmair 2000</a>). Of these, five studies did not compare tacrolimus versus cyclosporin in a randomised setting. In one study randomisation was performed in an alternate fashion (<a href="./references#CD008817-bbs2-0006" title="GriffithBP , BandoK , HardestyRL , ArmitageJM , KeenanRJ , PhamSM , et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation1994;57(6):848‐51. [MEDLINE: 7512292] KeenanRJ , DauberJH , IaconoA . Long term follow up clinical trial of tacrolimus versus cyclosporin for lung transplantation. Journal of Heart &amp; Lung Transplantation1998;17(1):58. KeenanRJ , KonishiH , KawaiA , ParadisIL , NunleyDR , IaconoAT , et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Annals of Thoracic Surgery1995;60(3):580‐4. [MEDLINE: 7545889] McCurryKR , ZaldonisDB , KeenanRJ , DauberJH , BauldoffGS , HattlerBG , et al. Long term follow‐up of a prospective, randomized trial of tacrolimus versus cyclosporine in human lung transplantation [abstract]. American Journal of Transplantation2002;2(Suppl 3):159. ">Keenan 1995</a>). This study design was classified as quasi‐randomised, and following our protocol inclusion criteria, the study was excluded from analysis for benefits. However, we carefully analysed the study of Keenan for harms, and the nature and incidence of harms in this study was not different from the included RCTs, Reasons for exclusions are described in <a href="./references#CD008817-sec2-0021" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD008817-sec2-0009"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, study methodology reporting was inadequate in the included studies (<a href="#CD008817-fig-0002">Figure 2</a>). All three studies were considered to be at high risk of bias because one or more of the components assessed were either at high risk of bias or unclear due to incomplete reporting. </p> <div class="figure" id="CD008817-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008817-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD008817-sec3-0020"> <h4 class="title">Allocation</h4> <p>Generation of the allocation sequence was reported in all three studies. The allocation sequence generation method was considered to be unclear in <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a>. <a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a> and <a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a>, which both used computer‐generated allocation sequencing, were assessed to be at low risk of bias. </p> <p>Allocation concealment methods were not reported in <a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a> or <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> and were considered to be unclear in terms of risk of allocation bias. <a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a> used a telephone‐based centralised method and was considered to be at low risk of bias regarding allocation concealment. </p> </section> <section id="CD008817-sec3-0021"> <h4 class="title">Blinding</h4> <p>All included studies indicated that they were open‐label and were considered to be at high risk of bias regarding blinding of patients and study personnel. </p> <p><a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a> reported that pathologists who examined transbronchial lung biopsy specimens were blinded to study drug assignment, but the impact of blinding outcome assessors to other outcome measures was not reported, and this study was therefore considered to carry an unclear risk of bias regarding blinding of outcome assessors. <a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a> and <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> were considered to be at high risk of bias regarding blinding of outcome assessors. </p> </section> <section id="CD008817-sec3-0022"> <h4 class="title">Incomplete outcome data</h4> <p>The included studies reported on incomplete outcome data and were not found to be at risk of attrition bias. </p> </section> <section id="CD008817-sec3-0023"> <h4 class="title">Selective reporting</h4> <p>Although we did not have access to study protocols, all three included studies reported on the most relevant clinical outcome measures. Therefore, the included studies were considered to be at low risk of selective outcome reporting bias. </p> </section> <section id="CD008817-sec3-0024"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a> and <a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a> were industry‐sponsored studies and considered to be at high risk of bias. No other potential risks of bias were found in <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a>. </p> </section> </section> <section id="CD008817-sec2-0010"> <h3 class="title" id="CD008817-sec2-0010">Effects of interventions</h3> <p>See: <a href="./full#CD008817-tbl-0001"><b>Summary of findings for the main comparison</b> Tacrolimus compared to cyclosporin for lung transplant recipients</a> </p> <section id="CD008817-sec3-0025"> <h4 class="title">Mortality</h4> <p>All three studies reported mortality. Overall, no significant difference in mortality was found between tacrolimus (49/205; 24%) and cyclosporin (47/208; 23%)(<a href="./references#CD008817-fig-00101" title="">Analysis 1.1</a> (3 studies, 413 participants): RR 1.06, 95% CI 0.75 to 1.49). </p> </section> <section id="CD008817-sec3-0026"> <h4 class="title">Acute rejection</h4> <p><a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a> and <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> reported acute rejection (defined as the number of patients who experienced at least one episode of rejection, and determined by clinical criteria or transbronchial lung biopsy). No significant difference was found between participants treated with tacrolimus (104/161; 65%) and cyclosporin (118/162; 73%)(<a href="./references#CD008817-fig-00102" title="">Analysis 1.2</a> (2 studies, 322 participants): RR 0.89, 95% CI 0.77 to 1.03). </p> <p><a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> reported the number of acute rejection episodes/100‐patient days. No significant difference in acute rejection episodes was found when tacrolimus (0.22 ± 0.3) was compared with cyclosporin (0.32 ± 0.42)(<a href="./references#CD008817-fig-00103" title="">Analysis 1.3</a> (1 study 74 participants): MD ‐0.10, 95% CI ‐0.27 to 0.07). </p> </section> <section id="CD008817-sec3-0027"> <h4 class="title">Bronchiolitis obliterans syndrome</h4> <p>All three studies reported the numbers of participants diagnosed with bronchiolitis obliterans syndrome, and all defined bronchiolitis obliterans according to the guidelines of the International Society for Heart and Lung Transplantation (<a href="./references#CD008817-bbs2-0014" title="CooperJD , BillinghamM , EganT , HertzMI , HigenbottamT , LynchJ , et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. Journal of Heart &amp; Lung Transplantation1993;12(5):713‐6. [MEDLINE: 8241207] ">Cooper 1993</a>). </p> <p>There were statistically significant fewer numbers of participants treated with tacrolimus (22/205; 11%) who developed bronchiolitis obliterans syndrome compared with those treated with cyclosporin (48/208; 23%)(<a href="./references#CD008817-fig-00104" title="">Analysis 1.4</a> (3 studies, 413 participants): RR 0.46, 95% CI 0.29 to 0.74). This statistically significant effect persisted when the random‐effects model was applied (RR 0.47, 95% CI 0.29 to 0.75). </p> </section> <section id="CD008817-sec3-0028"> <h4 class="title">Infection or sepsis</h4> <p><a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> reported infection as the total overall number of infections/100 patient‐days. No statistically significant difference in infections/100 patient‐days was observed among participants treated with tacrolimus (0.55 ± 0.31) compared with cyclosporin (0.7 ± 0.36)(<a href="./references#CD008817-fig-00105" title="">Analysis 1.5</a> (1 study, 149 participants): MD ‐0.15, 95% CI ‐0.30 to 0.00). </p> </section> <section id="CD008817-sec3-0029"> <h4 class="title">Quality of life</h4> <p>None of the included studies reported quality of life.</p> </section> <section id="CD008817-sec3-0030"> <h4 class="title">Any adverse event</h4> <p><a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a> reported on adverse effects (not including acute rejection, infection or bronchiolitis obliterans). It was reported that 6/124 (5%) participants in the tacrolimus group experienced an adverse event leading to treatment withdrawal (3 cytopenia; 3 neurotoxicity) compared with 11/125 (9%) participants in the cyclosporin group (3 cytopenia; 4 nephrotoxicity; 4 side effects)(<a href="./references#CD008817-fig-00106" title="">Analysis 1.6</a> (1 study, 249 participants): RR 0.55, 95% CI 0.21 to 1.44). </p> </section> <section id="CD008817-sec3-0031"> <h4 class="title">Treatment withdrawals</h4> <p>All three studies reported on treatment withdrawals. Treatment withdrawals were statistically less frequent in the tacrolimus group (14/205; 7%) compared with the cyclosporin group (54/208; 26%)(<a href="./references#CD008817-fig-00107" title="">Analysis 1.7</a> (3 studies 413 participants): RR 0.27, 95% CI 0.16 to 0.46). This effect persisted when the random‐effects model was applied (RR 0.27, 95% CI 0.16 to 0.46) Withdrawals were attributed to recurrent rejection episodes, occurrence of bronchiolitis obliterans, or adverse effects, or where participants often switched between drugs. </p> </section> <section id="CD008817-sec3-0032"> <h4 class="title">Lymphocytic bronchitis</h4> <p><a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a> reported lymphocytic bronchitis. The cumulative lymphocytic bronchitis B score in the study was defined as the sum of all B scores for each subject, excluding B scores in the setting of a confirmed bacterial or viral respiratory tract infection (<a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a>; <a href="./references#CD008817-bbs2-0027" title="HusainAN , SiddiquiMT , HolmesEW , ChandrasekharAJ , McCabeM , RadvanyR , et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. American Journal of Respiratory &amp; Critical Care Medicine1999;159(3):829‐33. [MEDLINE: 10051258] ">Husain 1999</a>) and the lymphocytic bronchitis score was significantly lower in patients treated with tacrolimus (0.7 ± 0.9) compared with cyclosporin (1.3 ± 1.2)(<a href="./references#CD008817-fig-00108" title="">Analysis 1.8</a> (1 study, 90 participants): MD ‐0.60, 95% CI ‐1.04 to ‐0.16). </p> </section> <section id="CD008817-sec3-0033"> <h4 class="title">Pneumonia (viral, bacterial, fungal)</h4> <p>None of the included studies reported on pneumonia.</p> </section> <section id="CD008817-sec3-0034"> <h4 class="title">Cytomegalovirus infection</h4> <p>None of the included studies reported on cytomegalovirus infection.</p> </section> <section id="CD008817-sec3-0035"> <h4 class="title">Cancer</h4> <p><a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a> and <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> reported cancer. No significant difference was seen in the numbers of participants diagnosed with cancer between tacrolimus (1/81; 1%) and cyclosporin (7/83; 8%)(<a href="./references#CD008817-fig-00109" title="">Analysis 1.9</a> (2 studies, 164 participants): RR 0.21, 95% CI 0.04 to 1.16). </p> </section> <section id="CD008817-sec3-0036"> <h4 class="title">Kidney function</h4> <p><a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a> reported kidney failure, defined as the number of participants who required chronic haemodialysis. Kidney failure was not significantly different between tacrolimus (3/44; 7%) and cyclosporin (2/46; 4%)(<a href="./references#CD008817-fig-00110" title="">Analysis 1.10</a> (1 study, 90 participants): RR 1.57, 95% CI 0.28 to 8.94). </p> <p>Kidney dysfunction was reported in all three studies and was defined as creatinine over 2.0 mg/dL (<a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a>), creatinine over 2.5 mg/dL (<a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a>), or a persistent increase in creatinine over 2 mg/dL or dialysis dependency (<a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a>). No statistically significant difference in kidney dysfunction was seen between the tacrolimus (43/205; 21%) and cyclosporin (31/208; 15%)(<a href="./references#CD008817-fig-00111" title="">Analysis 1.11</a> (3 studies, 413 participants): RR 1.41, 95% CI 0.93 to 2.14). </p> <p><a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> reported mean serum creatinine. Serum creatinine (mg/dL) was not significantly different in the tacrolimus group (1.6 ± 0.7 mg/dL) compared with the cyclosporin group (1.5 ± 0.4 mg/dL)(<a href="./references#CD008817-fig-00112" title="">Analysis 1.12</a> (1 study, 74 participants): MD 0.10 mg/dL, 95% CI ‐0.16 to 0.36). </p> </section> <section id="CD008817-sec3-0037"> <h4 class="title">Arterial hypertension</h4> <p><a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a> and <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> reported arterial hypertension. <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> defined arterial hypertension as the requirement for antihypertensive treatment; the condition was not defined by <a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a>. When analysed using a fixed‐effect model, arterial hypertension was found to be significantly less common in participants treated with tacrolimus (33/81; 41%) compared with cyclosporin (51/83; 61%)(<a href="./references#CD008817-fig-00113" title="">Analysis 1.13</a> (2 studies, 164 participants): RR 0.67, 95% CI 0.50 to 0.89). No significant difference was seen when the random‐effects model was applied (RR 0.54, 95% CI 0.17 to 1.73). </p> </section> <section id="CD008817-sec3-0038"> <h4 class="title">New‐onset diabetes mellitus</h4> <p><a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a> and <a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> reported new‐onset diabetes mellitus. When analysed using a fixed‐effect model, diabetes occurred more frequently in the tacrolimus group (18/81; 22%) compared with the cyclosporin group (4/83; 5%)(<a href="./references#CD008817-fig-00114" title="">Analysis 1.14</a> (2 studies, 164 participants): RR 4.24, 95% CI 1.58 to 11.40). No significant difference was seen when the random‐effects model was applied (RR 4.43, 95% CI 0.75 to 26.05). </p> </section> <section id="CD008817-sec3-0039"> <h4 class="title">Hyperlipidaemia and total cholesterol</h4> <p><a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a> reported the number of patients treated for hyperlipidaemia. No significant difference between tacrolimus (9/37; 24%) versus cyclosporin‐treated patients 15/37; 41%) was seen (<a href="./references#CD008817-fig-00115" title="">Analysis 1.15</a> (1 study, 74 participants): RR 0.60, 95% CI 0.30 to 1.20). </p> <p>None of the included studies reported total cholesterol concentrations.</p> </section> <section id="CD008817-sec3-0040"> <h4 class="title">Neurotoxic reaction</h4> <p><a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a> reported neurotoxicity. No significant difference was seen in the numbers of patients among whom treatment was withdrawn between the tacrolimus (3/124; 2%) cyclosporin (0/125; 0%) groups (<a href="./references#CD008817-fig-00116" title="">Analysis 1.16</a> (1 study, 249 participants): RR 7.06, 95% CI 0.37 to 135.19). </p> </section> <section id="CD008817-sec3-0041"> <h4 class="title">Hirsutism and gingival hyperplasia</h4> <p>None of the included studies reported on hirsutism or gingival hyperplasia.</p> </section> <section id="CD008817-sec3-0042"> <h4 class="title">Zero event correction</h4> <p><a href="./references#CD008817-bbs2-0001" title="HachemRR , ChakinalaMM , YusenRD , AloushAA , PattersonGA , TrulockEP . A prospective randomized study of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl 1):S127. HachemRR , YusenRD , ChakinalaMM , MeyersBF , LynchJP , AloushAA , et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(10):1012‐8. [MEDLINE: 17919621] ">Hachem 2007</a> reported the outcome 'treatment withdrawal' with zero events in both intervention groups. Therefore, we also performed a random‐effects meta‐analysis with empirical continuity correction of 0.01 in this zero event study. After zero event correction for treatment withdrawal, no significant difference remained with regard to treatment withdrawals for tacrolimus and cyclosporin (RR 0.25, 95% CI 0.02 to 2.50; P = 0.24). </p> </section> <section id="CD008817-sec3-0043"> <h4 class="title">Trial sequential analysis</h4> <p>Trial sequential analysis was performed for all outcome measures (<a href="./references#CD008817-bbs2-0051" title="EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC , ThorlundK . User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. Available from www.ctu.dk/tsa2011:1‐115. ">TSA 2011</a>). The required information size for the primary outcome measures was 2436 patients for mortality (<a href="#CD008817-fig-0003">Figure 3</a>), 2436 patients for bronchiolitis obliterans syndrome (<a href="#CD008817-fig-0004">Figure 4</a>), and 332 patients for acute rejection (<a href="#CD008817-fig-0005">Figure 5</a>). Hence, the required information size was almost reached to reject a 20% relative risk reduction in acute rejection. However, the cumulative Z‐curve reached the area of futility, indicating that we could reject a 20% relative risk reduction in acute rejection. Trial sequential analysis showed that the required information size to accept or reject a 15% relative risk reduction in acute rejection is 575 patients and assuming such a difference, neither the area of futility nor the required information size were reached (<a href="#CD008817-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD008817-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Trial sequential analysis of the effect of tacrolimus versus cyclosporin on mortality based on three studies (n = 413). The required information size of 2436 patients was calculated based on an observed mortality of 23% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 20 % in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%)" data-id="CD008817-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis of the effect of tacrolimus versus cyclosporin on mortality based on three studies (n = 413). The required information size of 2436 patients was calculated based on an observed mortality of 23% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 20 % in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%) </p> </div> </div> </div> <div class="figure" id="CD008817-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial sequential analysis of the effect of tacrolimus versus cyclosporin on bronchiolitis obliterans syndrome based on three studies (n = 413). The required information size of 2436 patients was calculated based on an observed bronchiolitis obliterans syndrome incidence of 23% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 20 % in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%)" data-id="CD008817-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis of the effect of tacrolimus versus cyclosporin on bronchiolitis obliterans syndrome based on three studies (n = 413). The required information size of 2436 patients was calculated based on an observed bronchiolitis obliterans syndrome incidence of 23% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 20 % in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%) </p> </div> </div> </div> <div class="figure" id="CD008817-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial sequential analysis of the effect of tacrolimus versus cyclosporin on acute rejection based on two studies (n = 323). The required information size of 332 patients was calculated based on an observed acute rejection incidence of 73% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 20 % in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%)" data-id="CD008817-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis of the effect of tacrolimus versus cyclosporin on acute rejection based on two studies (n = 323). The required information size of 332 patients was calculated based on an observed acute rejection incidence of 73% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 20 % in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%) </p> </div> </div> </div> <div class="figure" id="CD008817-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Trial sequential analysis of the effect of tacrolimus versus cyclosporin on acute rejection based on two studies (n = 323). The required information size of 332 patients was calculated based on an observed acute rejection incidence of 73% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 15% in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%)" data-id="CD008817-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis of the effect of tacrolimus versus cyclosporin on acute rejection based on two studies (n = 323). The required information size of 332 patients was calculated based on an observed acute rejection incidence of 73% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 15% in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%) </p> </div> </div> </div> <p>The required information size was not achieved for mortality and bronchiolitis obliterans syndrome, and none of the studies' sequential monitoring boundaries were broken by the cumulative Z‐curves. Trial sequential analysis was performed for secondary outcome measures, but neither the required information size, nor any of the areas of futility, was reached. </p> </section> <section id="CD008817-sec3-0044"> <h4 class="title">Subgroup analyses</h4> <p>We were unable to perform subgroup analyses of studies assessed to be at low risk of bias compared to those at high risk of bias. All included studies in this review were assessed to be at high risk of bias. Similarly, we were unable to perform subgroup analyses comparing adult and paediatric studies because all participants in the included studies were adults. None of the studies reported separately on results for recipients of single lung transplants compared with double lung transplants, and hence, were also unable to perform this subgroup analysis. </p> <p>Furthermore, we were unable to perform subgroup analysis of C2‐monitoring (2 hours post‐dose monitoring) of cyclosporin compared with cyclosporin dosing based on of trough levels (C0): all included studies applied cyclosporin dosing based on trough levels (C0). </p> <p>We were unable to perform subgroup analysis on tacrolimus versus oil‐based cyclosporin compared with tacrolimus versus microemulsion cyclosporin studies: the included studies used microemulsion or oral solution cyclosporin only. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008817-sec1-0006" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008817-sec1-0006"></div> <section id="CD008817-sec2-0011"> <h3 class="title" id="CD008817-sec2-0011">Summary of main results</h3> <p>We identified three studies with a total of 413 adult participants that assessed the effects of tacrolimus versus cyclosporin for lung transplant recipients. All studies were assessed to be at high risk of bias. </p> <p>Our systematic review generated a number of potentially important findings.</p> <p> <ul id="CD008817-lst1-0009"> <li> <p>Tacrolimus may be significantly superior to cyclosporin regarding the incidence of bronchiolitis obliterans syndrome, lymphocytic bronchitis, treatment withdrawal, and arterial hypertension. The finding for arterial hypertension was not confirmed when the random‐effects model was applied in the meta‐analysis. </p> </li> <li> <p>We found that cyclosporin may be superior to tacrolimus regarding new‐onset diabetes mellitus when assessed using the fixed‐effect model, but this was not confirmed when the random‐effects model was applied. </p> </li> <li> <p>No difference between the treatment groups was seen in mortality, incidence of acute rejection, infections/100 patient‐days, cancer, kidney failure, serum creatinine, hyperlipidaemia, and neurotoxic reactions. </p> </li> </ul> </p> <p>Trial sequential analysis indicated that the required information size was not reached in any of the meta‐analyses. Moreover, the cumulative Z‐curve did not cross the alpha spending monitoring boundaries in any of the meta‐analyses with statistically significant findings according to the traditional level of P &lt; 0.05. </p> <p>Likewise, the cumulative Z‐curve did not cross the beta spending monitoring boundaries of futility in the meta‐analyses that did not achieve statistically significant findings according to the traditional level of P &lt; 0.05. Acute rejection based on a relative risk reduction of 20% was reached in the area of futility, but not when a relative risk reduction of 15% was assumed. Accordingly, we were unable to exclude random errors in any of these comparisons. Further research is needed. </p> </section> <section id="CD008817-sec2-0012"> <h3 class="title" id="CD008817-sec2-0012">Overall completeness and applicability of evidence</h3> <p>This systematic review examined evidence from three RCTs that investigated the use of tacrolimus versus cyclosporin in lung transplant recipients. We were unable to obtain relevant data regarding all of our nominated outcome measures because of insufficient or absent reporting in the included studies. </p> <p>All included studies reported on three of our primary outcome measures: mortality, acute rejection and bronchiolitis obliterans syndrome; only one study reported on infection. None of the studies reported on our secondary outcomes: quality of life, pneumonia, cytomegalovirus infection, gingival hyperplasia, hirsutism, and total cholesterol concentration. </p> <p>It has been shown that two hours post‐dose cyclosporin monitoring (C2‐monitoring) in solid organ transplant recipients is the most accurate single time‐point predictor of one to four hour abbreviated area under the curve (<a href="./references#CD008817-bbs2-0030" title="IversenM , NilssonF , SipponenJ , EiskjaerH , MaredL , BerganS , et al. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study. Journal of Heart &amp; Lung Transplantation2009;28(9):919‐26. [MEDLINE: 19716045] ">Iversen 2009b</a>). Furthermore, C2‐monitoring has been found to be a sensitive predictor of acute cellular rejection in lung transplant recipients (<a href="./references#CD008817-bbs2-0030" title="IversenM , NilssonF , SipponenJ , EiskjaerH , MaredL , BerganS , et al. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study. Journal of Heart &amp; Lung Transplantation2009;28(9):919‐26. [MEDLINE: 19716045] ">Iversen 2009b</a>). Two included studies applied C2‐monitoring in all studies may have improved outcomes in cyclosporin group participants. </p> <p>In this review, a significant difference in treatment withdrawals was seen between the tacrolimus and cyclosporin groups. However, this difference may reflect common current practice that lung transplant recipients who develop bronchiolitis obliterans syndrome or experience recurrent episodes of acute rejection have their baseline immunosuppression therapy changed; it is not necessarily due to cyclosporin being less well tolerated or it being more toxic than tacrolimus (<a href="./references#CD008817-bbs2-0047" title="SnellGI , WestallGP . Immunosuppression for lung transplantation: evidence to date. Drugs2007;67(11):1531‐9. [MEDLINE: 17661526] ">Snell 2007</a>). </p> </section> <section id="CD008817-sec2-0013"> <h3 class="title" id="CD008817-sec2-0013">Quality of the evidence</h3> <p>We conducted this review according to the processes described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008817-bbs2-0024" title="HigginsJP , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). The quality and quantity of available evidence limited our findings and interpretations. The three studies assessed for this review included relatively few participants. Hence, risk of random errors is a potential explanation for our findings as suggested by our trial sequential analyses. It was also possible that participants in the included studies may not be representative of the general patient population. Of the three included studies, one was performed in the 1990s, and may not accurately reflect current practice regarding treatment and management of lung transplant patients (<a href="./references#CD008817-bbs2-0003" title="KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , TreedeH , et al. Prospective randomized two‐center trial comparing cyclosporine A (CsA) versus tacrolimus (Tac), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):45‐6. TreedeH , KlepetkoW , ReichenspurnerH , ZuckermannA , MeiserB , BirsanT , et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two‐center trial comparing two different immunosuppressive protocols. Journal of Heart &amp; Lung Transplantation2001;20(5):511‐7. [MEDLINE: 11343977] ZuckermannA , ReichenspurnerH , BirsanT , TreedeH , DeviatkoE , ReichartB , et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one‐year results of a 2‐center prospective randomized trial. Journal of Thoracic &amp; Cardiovascular Surgery2003;125(4):891‐900. [MEDLINE: 12698153] ZuckermannA , ReichenspurnerH , JakschP , TreedeH , WisserW , GroetznerJ , et al. Long term follow‐up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S76‐7. ">Zuckermann 2003</a>). </p> <p>Study follow‐up duration was up to three years, and therefore, there is no evidence on long‐term effects of tacrolimus and cyclosporin treatment on our outcome measures. Long‐term effects would be particularly relevant for outcome measures such as mortality, bronchiolitis obliterans syndrome, infection, and cancer. </p> <p>We explored the presence of statistical heterogeneity using the Chi² test and assessed heterogeneity using the I² test (<a href="./references#CD008817-bbs2-0023" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). The Chi² test is low powered in situations where meta‐analyses are conducted on studies with small sample sizes, or are few in number, as in this review. This means that while a statistically significant result may indicate a problem with heterogeneity, a non‐significant result should not be taken as evidence of no heterogeneity. To reflect our concerns about heterogeneity, we investigated both fixed‐effect and random‐effects models to provide more conservative estimates of effect. We found low heterogeneity (I² = 0%) for our primary outcome measures of mortality, acute rejection and bronchiolitis obliterans syndrome. No differences were seen between fixed‐effect and random‐effects model analyses for any of the primary outcome measures. We observed moderate heterogeneity regarding a secondary outcome measure: arterial hypertension (I² = 84%). A significant treatment difference was observed for this outcome when the fixed‐effect model was applied, but this disappeared when the random‐effects model was applied. </p> <p>Some outcomes of the included studies in our meta‐analysis include few patients and few events, and thus have wide confidence intervals around the estimate of effect, which influenced the precision of our results. </p> </section> <section id="CD008817-sec2-0014"> <h3 class="title" id="CD008817-sec2-0014">Potential biases in the review process</h3> <p>We conducted a comprehensive literature search for this review: inclusion and exclusion criteria were specified; data were extracted in triplicate; and data analysis was conducted according to the review's protocol (<a href="./references#CD008817-bbs2-0059" title="PenningaL , PenningaEI , MøllerCH , SteinbrüchelDA , GluudC . Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD008817] ">Penninga 2010b</a>). </p> <p>Risk of bias is known to impact on the estimated intervention effect; studies assessed at high risk of bias tend to overestimate beneficial intervention effects (<a href="./references#CD008817-bbs2-0035" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. [MEDLINE: 11730399] ">Kjaergard 2001</a>; <a href="./references#CD008817-bbs2-0039" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. [MEDLINE: 9746022] ">Moher 1998</a>; <a href="./references#CD008817-bbs2-0046" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [MEDLINE: 7823387] ">Schulz 1995</a>). Of the three include studies, two reported adequate generation of allocation sequencing; none reported adequate allocation concealment or blinded patients and personnel; one study reported blinding of the pathologist who examined transbronchial biopsies for rejection; two adequately addressed incomplete outcome data; all three reported on clinically relevant and reasonably expected outcome measures; and one appeared to be free of other components that could put the study at risk of bias. Accordingly, all studies were considered to be at high risk of bias. Therefore, it may be possible that the estimated intervention effect for all significant beneficial effects could be attributable to systematic errors. </p> <p>The risk of random error is higher when data are sourced from small evidence bases (or sample sizes for individual studies). Hence, the evidence base needs to be sufficiently large to reduce the risk of random error and increase the change of observing a true intervention effect (<a href="./references#CD008817-bbs2-0056" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). Accordingly, we also analysed data using trial sequential analysis. Trial sequential analysis is a statistical method that controls for random error caused by sparse data and formal or informal repetitive testing of accumulating data (<a href="./references#CD008817-bbs2-0052" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. Available from www.ctu.dk/tsa2011. ">TSA Manual 2011</a>). Trial sequential analysis provides information regarding the required evidence base and enables assessment of the risks of random errors when the required volume of evidence has not been reached. Furthermore, when no significant difference exists trial sequential analysis provides an area of futility, which may help in determining the need for further studies (<a href="./references#CD008817-bbs2-0052" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. Available from www.ctu.dk/tsa2011. ">TSA Manual 2011</a>). </p> <p>Trial sequential analysis of the outcome measures in this review showed that we could not exclude the possibility that beneficial effects found in the meta‐analyses were caused by random errors. </p> </section> <section id="CD008817-sec2-0015"> <h3 class="title" id="CD008817-sec2-0015">Agreements and disagreements with other studies or reviews</h3> <p>A meta‐analysis regarding tacrolimus versus cyclosporin in lung transplant recipients has been published (<a href="./references#CD008817-bbs2-0018" title="FanY , XiaoYB , WengYG . Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta‐analysis. Transplantation Proceedings2009;41(5):1821‐4. [MEDLINE: 19545736] ">Fan 2009</a>), and the results are slightly different from our systematic review. This might be explained by the following differences: we found one additional RCT that compared tacrolimus with cyclosporin, and we analysed data as intention‐to treat when possible (<a href="./references#CD008817-bbs2-0002" title="ReichenspurnerH , GlanvilleA , ChristinaA , LamaR , CarlosB , MarcE , et al. Complete 3 year analysis of a prospective randomized international multi‐center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients [abstract]. Journal of Heart &amp; Lung Transplantation2008;27(2 Suppl 1):S205‐6. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. One year complete follow‐up of a prospective randomized international investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2 Suppl 1):S82. ReichenspurnerH , GlanvilleA , KlepetkoW , LamaR , VerledenGM , BravoC , et al. Prospective randomized international multi‐center investigator driven study comparing Tac and CsA (+MMF/steroids) after lung transplantation ‐ interim analysis of 110 patients [abstract]. Journal of Heart &amp; Lung Transplantation2003;22(1 Suppl 1):S77. ReichenspurnerH , KlepetkoW , AboyounC , BravoC , EstenneM , HirtS , et al. Final 3 year analysis of a prospective randomized international multicenter investigator driven study comparing Tac and CsA (+ MMF/steroids) after lung transplantation in 274 patients [abstract]. Journal of Heart &amp; Lung Transplantation2007;26(2 Suppl 1):S211. TreedeH , GlanvilleA , KlepetkoW , LamaR , BravoC , EstenneM , et al. Risk of bronchiolitis obliterans syndrome is twice as high in cyclosporine treated patients in comparison to tacrolimus 3 years after lung transplantation: Results of a prospective randomized international trial of 248 patients. Journal of Heart &amp; Lung Transplantation2010;29(2 Suppl 1):S39. [EMBASE: 70194242] TreedeH , GlanvilleAR , KlepetkoW , AboyounC , VettorazziE , LamaR , et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart &amp; Lung Transplantation2012;31(8):797‐804. [PUBMED: 22554673] TreedeH , KlepetkoW , GlanvilleA , LamaR , BravoC , EstenneM , et al. Tacrolimus reduces the risk for bronchiolitis obliterans syndrome 3 years after lung‐transplantation by 50% in comparison to cyclosporine in a prospective randomized international trial of 248 patients. Transplant International2009;22(Suppl 2):54. ">Treede 2012</a>). Furthermore, we excluded one quasi‐RCT (<a href="./references#CD008817-bbs2-0006" title="GriffithBP , BandoK , HardestyRL , ArmitageJM , KeenanRJ , PhamSM , et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation1994;57(6):848‐51. [MEDLINE: 7512292] KeenanRJ , DauberJH , IaconoA . Long term follow up clinical trial of tacrolimus versus cyclosporin for lung transplantation. Journal of Heart &amp; Lung Transplantation1998;17(1):58. KeenanRJ , KonishiH , KawaiA , ParadisIL , NunleyDR , IaconoAT , et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Annals of Thoracic Surgery1995;60(3):580‐4. [MEDLINE: 7545889] McCurryKR , ZaldonisDB , KeenanRJ , DauberJH , BauldoffGS , HattlerBG , et al. Long term follow‐up of a prospective, randomized trial of tacrolimus versus cyclosporine in human lung transplantation [abstract]. American Journal of Transplantation2002;2(Suppl 3):159. ">Keenan 1995</a>) from the analyses of which was included in the <a href="./references#CD008817-bbs2-0018" title="FanY , XiaoYB , WengYG . Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta‐analysis. Transplantation Proceedings2009;41(5):1821‐4. [MEDLINE: 19545736] ">Fan 2009</a> meta‐analysis. We carefully analysed the study of Keenan (Keenan 1995) for harms, and the nature and incidence of harms in this study was not different from the included RCTs, Furthermore we performed all the meta‐analyses including data from the study from Keenan 1995, and all statistically significant outcomes remained statistically significant, and all statistically non‐significant outcomes remained statistically non‐significant. </p> <p>Observational data from the International Society of Heart and Lung Transplantation (ISHLT) registry showed that the percentage of recipients with reported acute rejection was highest in cyclosporin‐based regimens and lowest in tacrolimus‐based regimens (<a href="./references#CD008817-bbs2-0013" title="ChristieJD , EdwardsLB , AuroraP , DobbelsF , KirkR , RahmelAO , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐sixth Official Adult Lung and Heart‐Lung Transplantation Report‐2009. Journal of Heart &amp; Lung Transplantation2009;28(10):1031‐49. [MEDLINE: 19782285] ">Christie 2009</a>). In our review, we found a slight reduction in the number of patients affected by acute rejection in the tacrolimus group compared with the cyclosporin group, but this was not statistically significant (RR 0.88, 95% CI 0.76 to 1.03). </p> <p>Traditionally, clinicians administering immunosuppressive treatment for lung transplantation acquire substantial experience from knowledge regarding other types of organ transplantation. A meta‐analysis comparing tacrolimus versus cyclosporin in 3813 liver transplant recipients found tacrolimus to be superior to cyclosporin in improving patient survival, graft survival, and preventing acute rejection; however, tacrolimus was significantly more diabetogenic than cyclosporin (<a href="./references#CD008817-bbs2-0038" title="McAlisterVC , HaddadE , RenoufE , MalthanerRA , KjaerMS , GluudLL . Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta‐analysis. American Journal of Transplantation2006;6(7):1578‐85. [MEDLINE: 16827858] ">McAlister 2006</a>). A meta‐analysis comparing tacrolimus versus cyclosporin in 4102 kidney transplant recipients found tacrolimus to be superior to cyclosporin in improving graft survival and preventing acute rejection after kidney transplantation; however, tacrolimus was associated with increased post‐transplant diabetes, neurological, and gastrointestinal adverse effects (<a href="./references#CD008817-bbs2-0054" title="WebsterAC , TaylorRR , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003961.pub2] ">Webster 2005a</a>; <a href="./references#CD008817-bbs2-0055" title="WebsterAC , WoodroffeRC , TaylorRS , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta‐analysis and meta‐regression of randomised trial data. BMJ2005;331(7520):810. [MEDLINE: 16157605] ">Webster 2005b</a>). A systematic review with meta‐analysis comparing tacrolimus versus cyclosporin in 952 heart transplant recipients found tacrolimus to be superior to both formulations of cyclosporin with regard to hypertension, hyperlipidaemia, gingival hyperplasia, and hirsutism (<a href="./references#CD008817-bbs2-0042" title="PenningaL , MøllerCH , GustafssonF , SteinbrüchelDA , GluudC . Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta‐analyses and trial sequential analyses of randomised trials. European Journal of Clinical Pharmacology2010;66(12):1177‐87. [DOI: 10.1007/s00228‐010‐0902‐6] ">Penninga 2010a</a>). Tacrolimus was also found to be superior to microemulsion cyclosporin in heart transplant recipients with regard to mortality, biopsy‐proven acute rejection, hyperlipidaemia, hirsutism, and gingival hyperplasia (<a href="./references#CD008817-bbs2-0042" title="PenningaL , MøllerCH , GustafssonF , SteinbrüchelDA , GluudC . Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta‐analyses and trial sequential analyses of randomised trials. European Journal of Clinical Pharmacology2010;66(12):1177‐87. [DOI: 10.1007/s00228‐010‐0902‐6] ">Penninga 2010a</a>). Follow‐up in the randomised studies included in the meta‐analyses was between three months and five years among kidney transplant recipients (<a href="./references#CD008817-bbs2-0054" title="WebsterAC , TaylorRR , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003961.pub2] ">Webster 2005a</a>; <a href="./references#CD008817-bbs2-0055" title="WebsterAC , WoodroffeRC , TaylorRS , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta‐analysis and meta‐regression of randomised trial data. BMJ2005;331(7520):810. [MEDLINE: 16157605] ">Webster 2005b</a>); between three months and four years in liver transplant recipients (<a href="./references#CD008817-bbs2-0038" title="McAlisterVC , HaddadE , RenoufE , MalthanerRA , KjaerMS , GluudLL . Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta‐analysis. American Journal of Transplantation2006;6(7):1578‐85. [MEDLINE: 16827858] ">McAlister 2006</a>), and six months to five years in heart transplant recipients (<a href="./references#CD008817-bbs2-0042" title="PenningaL , MøllerCH , GustafssonF , SteinbrüchelDA , GluudC . Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta‐analyses and trial sequential analyses of randomised trials. European Journal of Clinical Pharmacology2010;66(12):1177‐87. [DOI: 10.1007/s00228‐010‐0902‐6] ">Penninga 2010a</a>). Follow‐up in the randomised studies on lung transplant recipients in this review ranged from 2.2 to 3 years. </p> <p>Our analysis did not find similar reductions in mortality or graft survival for lung transplant recipients treated with tacrolimus compared with cyclosporin as seen in liver, kidney and a subgroup of heart transplant recipients (<a href="./references#CD008817-bbs2-0038" title="McAlisterVC , HaddadE , RenoufE , MalthanerRA , KjaerMS , GluudLL . Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta‐analysis. American Journal of Transplantation2006;6(7):1578‐85. [MEDLINE: 16827858] ">McAlister 2006</a>; <a href="./references#CD008817-bbs2-0042" title="PenningaL , MøllerCH , GustafssonF , SteinbrüchelDA , GluudC . Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta‐analyses and trial sequential analyses of randomised trials. European Journal of Clinical Pharmacology2010;66(12):1177‐87. [DOI: 10.1007/s00228‐010‐0902‐6] ">Penninga 2010a</a>; <a href="./references#CD008817-bbs2-0054" title="WebsterAC , TaylorRR , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003961.pub2] ">Webster 2005a</a>; <a href="./references#CD008817-bbs2-0055" title="WebsterAC , WoodroffeRC , TaylorRS , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta‐analysis and meta‐regression of randomised trial data. BMJ2005;331(7520):810. [MEDLINE: 16157605] ">Webster 2005b</a>). Likewise, our analysis did not identify a similar reduction in numbers of lung transplant recipients affected by acute rejection who were treated with tacrolimus compared with cyclosporin as was observed in liver, kidney and a subgroup of heart transplant recipients (<a href="./references#CD008817-bbs2-0038" title="McAlisterVC , HaddadE , RenoufE , MalthanerRA , KjaerMS , GluudLL . Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta‐analysis. American Journal of Transplantation2006;6(7):1578‐85. [MEDLINE: 16827858] ">McAlister 2006</a>; <a href="./references#CD008817-bbs2-0042" title="PenningaL , MøllerCH , GustafssonF , SteinbrüchelDA , GluudC . Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta‐analyses and trial sequential analyses of randomised trials. European Journal of Clinical Pharmacology2010;66(12):1177‐87. [DOI: 10.1007/s00228‐010‐0902‐6] ">Penninga 2010a</a>; <a href="./references#CD008817-bbs2-0054" title="WebsterAC , TaylorRR , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003961.pub2] ">Webster 2005a</a>; <a href="./references#CD008817-bbs2-0055" title="WebsterAC , WoodroffeRC , TaylorRS , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta‐analysis and meta‐regression of randomised trial data. BMJ2005;331(7520):810. [MEDLINE: 16157605] ">Webster 2005b</a>). </p> <p>Tacrolimus was found to be more diabetogenic than cyclosporin among kidney and liver transplant recipients (<a href="./references#CD008817-bbs2-0038" title="McAlisterVC , HaddadE , RenoufE , MalthanerRA , KjaerMS , GluudLL . Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta‐analysis. American Journal of Transplantation2006;6(7):1578‐85. [MEDLINE: 16827858] ">McAlister 2006</a>; <a href="./references#CD008817-bbs2-0054" title="WebsterAC , TaylorRR , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003961.pub2] ">Webster 2005a</a>; <a href="./references#CD008817-bbs2-0055" title="WebsterAC , WoodroffeRC , TaylorRS , ChapmanJR , CraigJC . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta‐analysis and meta‐regression of randomised trial data. BMJ2005;331(7520):810. [MEDLINE: 16157605] ">Webster 2005b</a>), and this agrees in part with our findings for this review. We found tacrolimus to be inferior to cyclosporin with regard to diabetes when analysed using a fixed‐effect model, but no statistically significant difference was observed when a random‐effects model was applied. This review showed that tacrolimus in lung transplant recipients seems to be superior to cyclosporin with regard to hypertension (when applying the fixed‐effect model was applied), which is similar to findings among heart transplant recipients (<a href="./references#CD008817-bbs2-0042" title="PenningaL , MøllerCH , GustafssonF , SteinbrüchelDA , GluudC . Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta‐analyses and trial sequential analyses of randomised trials. European Journal of Clinical Pharmacology2010;66(12):1177‐87. [DOI: 10.1007/s00228‐010‐0902‐6] ">Penninga 2010a</a>). </p> <p>In heart transplant recipients, treatment differences were observed between tacrolimus versus oil‐based cyclosporin compared to tacrolimus versus microemulsion or oral cyclosporin formulations (<a href="./references#CD008817-bbs2-0042" title="PenningaL , MøllerCH , GustafssonF , SteinbrüchelDA , GluudC . Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta‐analyses and trial sequential analyses of randomised trials. European Journal of Clinical Pharmacology2010;66(12):1177‐87. [DOI: 10.1007/s00228‐010‐0902‐6] ">Penninga 2010a</a>). In this review, all included studies investigated microemulsion cyclosporin, and microemulsion or oral solution cyclosporin. Hence, we were unable to perform subgroup analyses on tacrolimus versus oil‐based cyclosporin compared to tacrolimus versus microemulsion or oral cyclosporin formulations. </p> <p>We found that a reduction in bronchiolitis obliterans syndrome seemed to occur in patients treated with tacrolimus compared with cyclosporin. This appears to be a significant finding because the ISHLT registry has identified the bronchiolitis obliterans syndrome and non‐cytomegalovirus infections as the most common causes of death more than one year after lung transplantation (<a href="./references#CD008817-bbs2-0013" title="ChristieJD , EdwardsLB , AuroraP , DobbelsF , KirkR , RahmelAO , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐sixth Official Adult Lung and Heart‐Lung Transplantation Report‐2009. Journal of Heart &amp; Lung Transplantation2009;28(10):1031‐49. [MEDLINE: 19782285] ">Christie 2009</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008817-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD008817-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008817-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis of the effect of tacrolimus versus cyclosporin on mortality based on three studies (n = 413). The required information size of 2436 patients was calculated based on an observed mortality of 23% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 20 % in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%)" data-id="CD008817-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Trial sequential analysis of the effect of tacrolimus versus cyclosporin on mortality based on three studies (n = 413). The required information size of 2436 patients was calculated based on an observed mortality of 23% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 20 % in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis of the effect of tacrolimus versus cyclosporin on bronchiolitis obliterans syndrome based on three studies (n = 413). The required information size of 2436 patients was calculated based on an observed bronchiolitis obliterans syndrome incidence of 23% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 20 % in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%)" data-id="CD008817-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Trial sequential analysis of the effect of tacrolimus versus cyclosporin on bronchiolitis obliterans syndrome based on three studies (n = 413). The required information size of 2436 patients was calculated based on an observed bronchiolitis obliterans syndrome incidence of 23% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 20 % in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis of the effect of tacrolimus versus cyclosporin on acute rejection based on two studies (n = 323). The required information size of 332 patients was calculated based on an observed acute rejection incidence of 73% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 20 % in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%)" data-id="CD008817-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Trial sequential analysis of the effect of tacrolimus versus cyclosporin on acute rejection based on two studies (n = 323). The required information size of 332 patients was calculated based on an observed acute rejection incidence of 73% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 20 % in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis of the effect of tacrolimus versus cyclosporin on acute rejection based on two studies (n = 323). The required information size of 332 patients was calculated based on an observed acute rejection incidence of 73% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 15% in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%)" data-id="CD008817-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Trial sequential analysis of the effect of tacrolimus versus cyclosporin on acute rejection based on two studies (n = 323). The required information size of 332 patients was calculated based on an observed acute rejection incidence of 73% in the cyclosporin group in the meta‐analysis (Pc); a relative risk reduction (RRR) of 15% in the tacrolimus group; a type I error (α) of 5%; a type II error (β) of 20%, and the observed heterogeneity in the meta‐analysis (I² = 0%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 1 Mortality." data-id="CD008817-fig-00101" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 2 Acute rejection." data-id="CD008817-fig-00102" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 2 Acute rejection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 3 Acute rejection (episodes/100 patient‐days)." data-id="CD008817-fig-00103" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 3 Acute rejection (episodes/100 patient‐days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 4 Bronchiolitis obliterans syndrome." data-id="CD008817-fig-00104" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 4 Bronchiolitis obliterans syndrome.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 5 Infection or sepsis (episodes/100 patient‐days)." data-id="CD008817-fig-00105" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 5 Infection or sepsis (episodes/100 patient‐days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 6 Adverse events." data-id="CD008817-fig-00106" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 7 Treatment withdrawal." data-id="CD008817-fig-00107" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 7 Treatment withdrawal.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 8 Lymphocytic bronchitis score." data-id="CD008817-fig-00108" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 8 Lymphocytic bronchitis score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 9 Cancer." data-id="CD008817-fig-00109" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 9 Cancer.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 10 Kidney failure." data-id="CD008817-fig-00110" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 10 Kidney failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 11 Kidney dysfunction." data-id="CD008817-fig-00111" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 11 Kidney dysfunction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 12 Creatinine." data-id="CD008817-fig-00112" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 12 Creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 13 Arterial hypertension." data-id="CD008817-fig-00113" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 13 Arterial hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 14 New‐onset diabetes mellitus." data-id="CD008817-fig-00114" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 14 New‐onset diabetes mellitus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 15 Hyperlipidaemia." data-id="CD008817-fig-00115" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 15 Hyperlipidaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008817-fig-00116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/urn:x-wiley:14651858:media:CD008817:CD008817-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_t/tCD008817-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tacrolimus versus cyclosporin, Outcome 16 Neurotoxicity." data-id="CD008817-fig-00116" src="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Tacrolimus versus cyclosporin, Outcome 16 Neurotoxicity.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-fig-00116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/media/CDSR/CD008817/image_n/nCD008817-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008817-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tacrolimus compared to cyclosporin for lung transplant recipients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tacrolimus compared to cyclosporin for lung transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Lung transplant recipients <br/> <b>Intervention:</b> Tacrolimus <br/> <b>Comparison:</b> Cyclosporin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Cyclosporin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tacrolimus</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b> <br/> Mortality at latest follow‐up <br/> Follow‐up: 2.2 to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.06</b> <br/> (0.75 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>413 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>226 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> <br/> (169 to 337) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>196 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>208 per 1000</b> <br/> (147 to 292) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acute rejection</b> <br/> The number of patients who experienced at least one episode of rejection <br/> Follow‐up: mean 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.89</b> <br/> (0.77 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>323 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>728 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>648 per 1000</b> <br/> (561 to 765) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>700 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b> <br/> (539 to 735) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Bronchiolitis obliterans syndrome</b> <br/> The number of patients diagnosed with the bronchiolitis obliterans syndrome <br/> Follow‐up: 2.2 to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.46</b> <br/> (0.29 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>413 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>231 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>106 per 1000</b> <br/> (67 to 171) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>208 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> <br/> (60 to 154) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Infection</b> <br/> The number of overall infections per 100 patient days <br/> Follow‐up: mean 1.4 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean infection in the intervention groups was <br/> <b>0.15 lower</b> <br/> (0.3 lower to 0 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal</b> <br/> the number of patients stopping the assigned drug intervention <br/> Follow‐up: 2.2 to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> <br/> (42 to 119) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.27</b> <br/> (0.16 to 0.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>413 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Arterial hypertension</b> <br/> Follow‐up: 2.2 to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.67</b> <br/> (0.5 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>164 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>614 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>412 per 1000</b> <br/> (307 to 547) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>599 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>401 per 1000</b> <br/> (300 to 533) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Diabetes mellitus</b> <br/> Follow‐up: 2.2 to 3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.24</b> <br/> (1.58 to 11.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>164 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> <br/> (76 to 549) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>187 per 1000</b> <br/> (70 to 502) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹All included studies were at high risk of bias as assessed using the Cochrane risk of bias tool <br/> ²Large and consistent intervention effect in the included studies <br/> ³The only included study was assessed as high risk of bias using the Cochrane risk of bias tool </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tacrolimus compared to cyclosporin for lung transplant recipients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/full#CD008817-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008817-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tacrolimus versus cyclosporin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.75, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.77, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Acute rejection (episodes/100 patient‐days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Bronchiolitis obliterans syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.29, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Infection or sepsis (episodes/100 patient‐days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Treatment withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.16, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Lymphocytic bronchitis score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.04, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Kidney failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Kidney dysfunction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.93, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Arterial hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.50, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 New‐onset diabetes mellitus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.43 [0.75, 26.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Hyperlipidaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Neurotoxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tacrolimus versus cyclosporin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008817.pub2/references#CD008817-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008817.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008817-note-1205">Español</a> </li> <li class="section-language"> <a class="" href="fr#CD008817-note-1204">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008817\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008817\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008817\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008817\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008817\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008817.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008817.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008817.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008817.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008817.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727851062"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008817.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727851066"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008817.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb6268da69368',t:'MTc0MDcyNzg1MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 